Free Research Reports on CHLN, MHR, MVIS and NVGN Issued by the Bedford Report
Read Full Article • Fri, Apr 05, 5:09am
Which other executives work with
David Seaton? Click to meet them now.
SEC Center Application
Just Released!
LAST UPDATED: 10/13/2012, 12:27 PM EDT
David R. Seaton - Chief Financial Officer. Mr. Seaton has been the Chief Financial Officer of Novogen Limited since 1999. Mr. Seaton is a graduate in Business Studies and holds a Master of Commerce degree from the University of New South Wales. He has completed Management Development programs at Northwestern University in Chicago, Illinois, Duke University in Durham, North Carolina and the London Business School. He has had over 20 years experience in the pharmaceutical industry. Prior to joining Novogen Limited he was the Finance Director of GlaxoWellcome Australia Ltd. Mr. Seaton was also Finance Director of Wellcome Australia Limited prior to its merger with Glaxo in 1995. Mr. Seaton has been the Chief Financial Officer and Secretary of Marshall Edwards since 2000. He has been a Director and the Secretary of Glycotex, Inc since September 2005. Mr. Seaton was appointed Chief Financial Officer of Glycotex, Inc. in November 2006. Mr. Seaton was appointed acting CEO of Novogen Limited and Marshall Edwards, Inc. on December 1, 2009. Closing balance represents the shareholding at the time the key management personnel's employment ceased with the company.
PassFail added 3 new financial items to our total of over 8 Videos, Articles, Blogs, & Podcasts on Novogen Ltd.. We update our news every 15 minutes from over 24,479 sources. We are finance.
Read Full Article • Fri, Apr 05, 5:09am
Read Full Article • Thu, Apr 04, 1:29pm
Read Full Article • Wed, Apr 03, 1:10pm
Read Full Article • Mon, Mar 25, 1:23pm
Read Full Article • Thu, Feb 21, 2:27am
Read Full Article • Wed, Feb 20, 5:15am
Read Full Article • Tue, Feb 19, 11:30am
Read Full Article • Wed, Jan 02, 7:02am
David R. Seaton - Chief Financial Officer. Mr. Seaton has been the Chief Financial Officer of Novogen Limited since 1999. Mr. Seaton is a graduate in Business Studies and holds a Master of Commerce degree from the University of New South Wales. He has completed Management Development programs at Northwestern University in Chicago, Illinois, Duke University in Durham, North Carolina and the London Business School. He has had over 20 years experience in the pharmaceutical industry. Prior to joining Novogen Limited he was the Finance Director of GlaxoWellcome Australia Ltd. Mr. Seaton was also Finance Director of Wellcome Australia Limited prior to its merger with Glaxo in 1995. Mr. Seaton has been the Chief Financial Officer and Secretary of Marshall Edwards since 2000. He has been a Director and the Secretary of Glycotex, Inc since September 2005. Mr. Seaton was appointed Chief Financial Officer of Glycotex, Inc. in November 2006. Mr. Seaton was appointed acting CEO of Novogen Limited and Marshall Edwards, Inc. on December 1, 2009. Closing balance represents the shareholding at the time the key management personnel's employment ceased with the company.
David Seaton salary this year was $388,345 @passfail #PASSFAIL
